Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486055 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
A Phase 1 study, sponsored by BPGbio.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02486055 is a Phase 1 study that has completed, run by BPGbio. The registered enrollment target is 20 participants.
The verdict
NCT02486055, a Phase 1 study, has completed, sponsored by BPGbio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label, Phase I study of the bioavailability and safety of BPM31510 in healthy subjects dosed 2 or 3 times daily for 4 days, after an initial cohort of 6 subjects receiving a single dose (pre-study cohort). The pre-study cohort subjects will receive 1600 mg as a single administration. Cohort 1 and Cohort 2 will consist of 10 patients each. The cohorts may be enrolled sequentially.
Interventions
- DRUG BPM31510 Oral Nanosuspension 4%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02486055
The ClinicalTrials.gov registry entry for NCT02486055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BPGbio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BPM31510 Oral Nanosuspension 4% is the first listed.
NCT02486055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02486055 about?
NCT02486055 is a clinical study titled "A Safety Study of Orally Administered BPM31510 in Healthy Subjects". This is an open-label, Phase I study of the bioavailability and safety of BPM31510 in healthy subjects dosed 2 or 3 times daily for 4 days, after an initial cohort of 6 subjects receiving a single dose (pre-study cohort). The pre-study cohort subjects will receive 1600 mg as a single administration....
What is the current status of trial NCT02486055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-11. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02486055?
The interventions under investigation include: BPM31510 Oral Nanosuspension 4% (DRUG).
Who is sponsoring clinical trial NCT02486055?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.